ArrowMark Colorado Holdings’s Achillion Pharmaceuticals ACHN Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-935,987	Closed	-$3.47M	–	358
2018 Q1	$3.47M	Hold	935,987	–	–	0.03%	238
2017 Q4	$2.7M	Hold	935,987	–	–	0.03%	243
2017 Q3	$4.2M	Buy	935,987 +252,368	+37%	+$1.12M	0.05%	224
2017 Q2	$3.14M	Buy	+683,619	New	+$2.75M	0.04%	228
2016 Q4	–	Sell	-29,194	Closed	-$236K	–	487
2016 Q3	$236K	Hold	29,194	–	–	﹤0.01%	279
2016 Q2	$228K	Hold	29,194	–	–	﹤0.01%	270
2016 Q1	$225K	Sell	29,194 -1,650	-5%	-$12.1K	0.01%	256
2015 Q4	$333K	Hold	30,844	–	–	0.01%	259
2015 Q3	$213K	Buy	30,844 +544	+2%	+$4.43K	0.01%	275
2015 Q2	$268K	Sell	30,300 -24,950	-45%	-$236K	0.01%	292
2015 Q1	$545K	Buy	+55,250	New	+$690K	0.01%	236
2013 Q3	–	Sell	-95,891	Closed	-$784K	–	317
2013 Q2	$784K	Buy	+95,891	New	+$732K	0.21%	70

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ArrowMark Colorado Holdings's ACHN Position: Q2 2018 in Review

ArrowMark Colorado Holdings sold out of Achillion Pharmaceuticals (ACHN) in Q2 2018, closing a stake of 935,987 shares — an estimated $3.47M sold.

ArrowMark Colorado Holdings first reported a position in ACHN in Q2 2013 and held it in 12 quarters. The position peaked at $4.2M in Q3 2017. 124 funds tracked by Wall St. Rank hold ACHN as of Q2 2018.

ArrowMark Colorado Holdings reported no remaining Achillion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
ArrowMark Colorado Holdings sold 935,987 Achillion Pharmaceuticals shares in Q2 2018, an estimated $3.47M.
ArrowMark Colorado Holdings first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
ArrowMark Colorado Holdings's Achillion Pharmaceuticals position peaked at $4.2M in Q3 2017.
124 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2018.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2018, filed 14 Aug 2018.